A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis

Journal of Drugs in Dermatology

Volumn 10, Issue 7, 2011, Pages 735-743

  Emer, Jason J ^a   Frankel, Amylynne ^a   Sohn, Andrew ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PHYSICIAN GLOBAL ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TARGET LESION SYMPTOM SCORE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CETOMACROGOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERAL OIL; PETROLATUM; SINGLE-BLIND METHOD; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053071144     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Leung DY, Boguniewicz M, Howell MD, et al. New insight into atopic dermatitis. J Clin Invest. 2004;113:651-657.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-160. (Pubitemid 36092023)
3. Przybilla B, Eberlein-Konig B, Rueff F. Practical management of atopic eczema. Lancet. 1994;343:1342-1346. (Pubitemid 24162579)
4. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allerg Clin Immunol. 2003;112:140-150.
5. Paller AS, Orlow SJ. Fearing the flare: Patient outlook on the management of atopic dermatitis (ISOLATE Study). J Am Acad Dermatol. 2005;52:AB14.
6. Simpson EL. Atopic dermatitis: A review of topical treatment options. Curr Med Res Opin. 2010;26:633-640.
7. Haapasaari KM, Risteli J, Koivukangas V, et al. Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and bethamethasone on collagen synthesis in human skin in vivo. Acta Derm Venereol. 1995;75:269-271.
8. Haapasaari KM, Risteli J, Karvonen J, et al. Effect of hydrocortisone, methylprednisolone acetonate and mometasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol. 1997;10:261-264. (Pubitemid 28021552)
9. Sheu HM, Lee JY, Chai CY, et al. Depletion of stratum corneum intracellular lipid lamellae and barrier function abnormalities after longterm topical corticosteroids. Br J Dermatol. 1997;136:884-890. (Pubitemid 27283520)
10. Kolbe L, Kligman AM, Schreiner V, et al. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 2001;7:73-77. (Pubitemid 32409572)
11. Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment comprises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456-464. (Pubitemid 36298433)
12. Du Vivier A. Tachyphlaxis to topically applied steroids. Arch Dermatol. 1976;112:1245-1248.
13. Zheng PS, Lavker RM, Lehmann P, et al. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol. 1984;84:345-352. (Pubitemid 14131459)
14. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984;1:246-253. (Pubitemid 14078604)
15. Urpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol. 1986;115:475-484. (Pubitemid 16025343)
16. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol. 1988;118:517-522.
17. Turpeinen M, Lehttokoski-Lehtiniemi E, Leisti S, et al. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol. 1988;5:276-279. (Pubitemid 19027867)
18. Tuneja C. Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol. 2010;9:372-376.
19. Werfel T. Topical use of pimecrolimus in atopic dermatitis: Update on the safety and efficacy. J Dtsch Dermatol Ges. 2009;7:739-742.
20. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24:985-294.
21. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology. 2002;205:271-277.
22. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15:169-178. (Pubitemid 39214578)
23. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
24. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
25. Kaufmann R, Folster-Holst R, Hoger P, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol. 2004;114:1183-1188. (Pubitemid 39469163)
26. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88:969-973.
27. Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure to infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. Exp Dermatol. 2006;15:138-141.
28. Vergnanini AL, Aoki V, Takaoka R, et al. Comparative effects of pimecrolimus cream vehicle and three commercially available moisturizers on skin hydration and transepidermal water loss. J Dermatolog Treat. 2010;21:126-129.
29. Kircik, L. A nonsteroidal lamellar matrix cream containing palmyitoethanolamide for the treatment of atopic dermatitis. J Drugs Dermatol. 2010;9:334-348.
30. Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: A multicenter, randomized, vehicle-controlled study. J Pediatr. 2008;152:854-859.
31. Abramovits W, Perlmutter A. MimyX cream. Skinmed. 2006;5:29-30.
32. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today (Barc). 2008;44:751-755.
33. Onset Therapeutics. Hylatopic Emollient Foam. Available at: http://www.onsettx.com/docs/hylatopic/Hylatopic-PI-2611-pf-Rev-2. pdf. Accessed July 29, 2010.
34. Proksch E, Folster-Holst R, Brautigam M, et al. Role of epidermal barrier in atopic dermatitis. J Dtsch Dermatol Ges. 2009;7:899-910.
35. Kezic S, Kemperman PM, Kister ES, et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol. 2008;128:2117-2119. (Pubitemid 352001213)
36. Sugarman JL, Fluhr JW, Fowler AJ, et al. The objective severity assessment of atopic dermatitis score: An objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol. 2003;139:1417-1422. (Pubitemid 37433131)
37. Di Nardo A, Wertz P, Giannetti A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78:27-30. (Pubitemid 28103674)
38. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144:1-9.
39. Grice K, Sattar H, Baker H, et al. The relationship of transepidermal water loss to skin temperature in psoriasis and eczema. J Invest Dermatol. 1975;64:313-315.
40. Christophers E, Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res. 1987;279:48S-51S.
41. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13:721-730. (Pubitemid 39625218)
42. Buchau AS, Schauber J, Au N, et al. Pimecrolimus enhances innate immune function of normal human keratinocytes (conference abstract). J Invest Dermatol. 2007;127:130S.
43. Cork M, Robinson D, Vasilopoulos Y, et al. Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. J Am Acad Dermatol. 2006;54:AB3.
44. Cork MJ, Varghese J, Hadcraft J, et al. Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - implications for therapy (conference abstract). J Invest Dermatol. 2007;127:45S.
45. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to four years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53:186S-194S.
46. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:48S-64S.
47. Langley RG, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol. 2008;25:301-307. (Pubitemid 351813950)
48. U.S. Food and Drug Administration. FDA Approves Updated Labeling with Boxed Warning and Meidcation Guide for Two Eczema Drugs, Elidel and Protopic. 2006. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm153941.htm. Accessed May 6, 2010.
49. Loden M, Olsson H, Skare L, et al. Instrumental and sensory evaluation of the frictional response of the skin following a single application of five moisturizing creams. J Soc Cosmet Chem. 1992;43:13-20.
50. Mao-Qiang M, Brown BE, Wu-Pong S, et al. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131:809-816.
51. Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions is never redeemed: Primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59:27-33.
52. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56:211-216. (Pubitemid 46074250)
53. Feldman S, Camacho F, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81-83. (Pubitemid 46908856)